The outlook has changed a great deal. In the past ten years, several treatments have been approved worldwide, and two more arrived in late 2025 and 2026. In India, a generic version of the oral medicine risdiplam has also become available, widening access.
This guide explains the signs to watch for, how SMA Type 2 is diagnosed, what treatment looks like in 2026, how families in India can access it and where families in Odisha can begin paediatric neurology care at HMCH
What Is SMA Type 2?
SMA Type 2 is the intermediate form of spinal muscular atrophy, a condition seen in about 1 in 10,000 live births (Healthline). It is also called intermediate SMA or Dubowitz disease. It is less severe than SMA Type 1 and more severe than Type 3.
SMA is a motor neuron disease, not a disease of the muscles themselves. It damages the nerve cells in the spinal cord, called motor neurons or anterior horn cells, that carry signals to the muscles. Without those signals, the muscles weaken and shrink.
The muscles closest to the centre of the body, such as the hips, thighs, shoulders and back, are affected most. The legs are usually weaker than the arms (MDA).
One point matters to every parent: SMA does not affect thinking, learning or feeling. Children with SMA Type 2 are often bright, curious and very social. With the right support, they go to school and make friends like any other child.
SMA Type 2 Symptoms and When They Start
SMA Type 2 symptoms usually begin between 6 and 18 months of age. Babies often look healthy at birth and may roll and sit on time (Healthline). Then progress slows or stops, and the child does not stand or walk without help.
Common signs include:
- Low muscle tone (hypotonia). The child feels “floppy” when lifted.
- Weak legs. Weakness is usually worse in the legs than the arms.
- Absent or reduced reflexes (areflexia). A doctor finds this on examination.
- Fine tremor or twitching. This may show in the fingers or the tongue (tongue fasciculations).
- A curving spine (scoliosis). This often develops as the back muscles weaken.
- Tight joints (contractures). These can affect the hips, knees and elbows.
- Breathing and feeding difficulty. Weak chest muscles can cause a weak cough, frequent chest infections and tiring meals.
- Slow weight gain.
Warning signs for parents. See a paediatric neurologist if your child is not sitting steadily by 9 months, sits but loses the ability to stand with support, feels unusually floppy, or has a weak cough with repeated chest infections. Early diagnosis matters, because treatment works best before more motor neurons are lost.
What Causes SMA Type 2? SMN1, SMN2 and Inheritance
About 95% of SMA cases are caused by a missing or faulty SMN1 gene on chromosome 5 (Cureus case report and review, 2020). This gene makes the survival motor neuron (SMN) protein, which motor neurons need to stay alive. The most common fault is a deletion of a section called exon 7.
A second gene, SMN2, acts as a partial backup. It makes only a small amount of working SMN protein. The more copies of SMN2 a child has, the milder the condition tends to be. Children with SMA Type 2 usually have three copies, while those with Type 1 usually have two (Healthline).
How is SMA Type 2 inherited?
SMA is autosomal recessive. A child is affected only when they inherit a faulty SMN1 gene from both parents. Parents who carry one faulty copy are healthy and usually don’t know they are carriers.
When both parents are carriers, each pregnancy has a 1 in 4 chance of a child with SMA, a 1 in 2 chance of a carrier child and a 1 in 4 chance of a child with neither. In India, about 3% of people are estimated to carry an SMN1 change (Ministry of Health and Family Welfare, SMA information note). That’s roughly 1 in 33 people.
How Is SMA Type 2 Diagnosed?
A genetic blood test confirms SMA Type 2. It checks for a missing or faulty SMN1 gene and counts the copies of SMN2. Because about 95% of cases involve SMN1, this single test confirms most diagnoses (Cureus, 2020).
Your doctor may also order:
- Electromyography (EMG) and nerve conduction studies. These show whether weakness comes from the nerves or the muscles. In SMA, the pattern points to the motor neurons.
- Creatine kinase (CK) blood test. CK is usually normal or only slightly raised in SMA. This helps rule out muscular dystrophy.
- Breathing and swallowing checks. These set a baseline for future care.
The SMN2 copy number helps doctors predict how the condition may progress and plan treatment.
Testing before or soon after birth
If SMA runs in your family, carrier testing for both parents and prenatal diagnosis are available. Some countries now screen every newborn for SMA. England, for example, plans full national newborn screening by October 2027 (Patient Worthy). India does not yet have universal SMA newborn screening.
SMA Type 2 vs Type 1 vs Type 3
Doctors group SMA into types by the age symptoms start and the highest movement milestone a child reaches. Today, most specialists see SMA as a continuum rather than fixed boxes (MDA). The table shows the typical untreated pattern.
Feature | SMA Type 1 | SMA Type 2 | SMA Type 3 |
Usual onset | Before 6 months | 6 to 18 months | After 18 months |
Highest motor milestone | Does not sit alone | Sits, but does not walk alone | Walks, may lose it later |
Breathing involvement | Severe, early | Moderate, increases with time | Usually mild |
Typical SMN2 copies | 2 | 3 | 3 to 4 |
Untreated outlook | Often under 2 years | Many reach adulthood | Usually normal lifespan |
These are typical patterns, not predictions for any one child. Treatment can change them.
SMA Type 2 Treatment Options in 2026
There’s no cure for SMA Type 2 yet, but disease-modifying therapies can slow, stop or partly reverse the loss of movement. As of October 2026, five medicines are approved in the United States. Only one, risdiplam, is approved in India (Gulati et al., Journal of Neuromuscular Diseases, 2025).
Treatments that restore SMN protein
These medicines raise the level of SMN protein, which protects the motor neurons that remain.
Medicine | How it works | How it’s given | Who it’s for | Approved in India? |
Risdiplam (Evrysdi; generic Natsmart) | SMN2 splicing modifier | Oral liquid, once a day at home | All ages from 2 months | Yes |
Nusinersen (Spinraza) | Antisense oligonucleotide acting on SMN2 | Injection into the spinal fluid, every 4 months after loading doses | Children and adults | No |
Onasemnogene abeparvovec IV (Zolgensma) | Gene replacement therapy | One-time IV infusion | Children under 2 years | No |
Onasemnogene abeparvovec intrathecal (Itvisma) | Gene replacement therapy | One-time injection into the spinal fluid, fixed dose | Ages 2 years and older | No, as of October 2026 |
Itvisma changed the picture for older children. On 24 November 2025, the US FDA approved Itvisma, the first gene therapy for people with SMA aged 2 and older (NeurologyLive, November 2025). Before this, gene therapy was limited to babies under 2, which left out most children with SMA Type 2. Many older guides still say gene therapy is only for infants.
Risdiplam has the longest record in this group. In the SUNFISH study of people aged 2 to 25 with Type 2 or Type 3 SMA, motor gains seen in the first year were maintained through four years of treatment (Genentech data via TipRanks, 2023).
The new muscle-targeted add-on: apitegromab (Isembyld)
In September 2026, the FDA approved the first SMA medicine that acts on the muscle itself. Apitegromab (Isembyld) blocks myostatin, a protein that limits muscle growth (Epocrates, September 2026). It is not a replacement for SMN therapy. It’s given alongside it.
Key facts:
- Who: children and adults aged 2 and older who already take an SMN2-targeted medicine such as risdiplam or nusinersen.
- Evidence: in the SAPPHIRE trial of 188 non-walking patients aged 2 to 21, 34.2% on apitegromab gained 3 or more points on a standard motor scale, compared with 13.5% on placebo (Epocrates).
- How: an IV infusion every 4 weeks.
- Caution: the FDA noted an increased risk of fractures, including serious ones (Consultant360).
Itvisma and Isembyld are US approvals. Neither is approved in India as of October 2026. Ask your child’s neurologist about access routes, clinical trials and whether they suit your child.
Which treatment is right depends on your child’s age, weight, SMN2 copies, current strength and access. A paediatric neurologist with SMA experience should guide this decision. Our neurology team
Supportive Care: Breathing, Spine, Hips and Feeding
Medicines treat the cause, but day-to-day care keeps a child with SMA Type 2 healthy and comfortable. Even with treatment, weak muscles still affect the chest, spine and hips (SMA UK). That’s why care is led by a multidisciplinary team, not one doctor.
Breathing
Breathing problems are the most serious risk in SMA Type 2. Weak chest muscles make it hard to cough and clear mucus, so a simple cold can turn into a chest infection quickly.
- Sleep studies. Breathing often weakens first during sleep. A useful sleep study measures carbon dioxide as well as oxygen, because oxygen alone can miss night-time problems (SMA UK).
- Airway clearance. Chest physiotherapy, suction and a cough assist machine help clear secretions.
- Non-invasive ventilation (NIV). A mask-based machine supports breathing, usually at night.
- Early antibiotics. Contact your team early if your child has more mucus, fever, faster breathing or unusual sleepiness.
- Vaccinations. Keep routine, flu and pneumococcal vaccines up to date for your child and the family.
Spine and hips
Scoliosis develops in many children with SMA Type 2. A custom spinal brace can support sitting and may slow the curve, but it won’t prevent it (SMA UK). Some children later need spinal surgery. Hips can slip out of place, so regular X-rays are part of follow-up.
Movement and daily life
A neuromuscular physiotherapist plans stretches and active exercise to prevent stiff joints. Supported standing in a standing frame helps bones, breathing and digestion. Swimming and hydrotherapy are often enjoyable. Many children use a manual or power wheelchair, which gives real independence at school and play. paediatric physiotherapy
Feeding and nutrition
Chewing and swallowing can be tiring. A dietitian checks calories, calcium and vitamin D for bone health. If swallowing isn’t safe or weight gain is poor, a feeding tube may be advised. Daily tooth and mouth cleaning matters too, because it reduces bacteria that can cause chest infections if food or saliva goes down the wrong way.
Make an emergency plan. Keep a written plan with your child’s diagnosis, breathing settings, airway clearance routine and specialist contacts. Share it with any emergency team, because many casualty doctors rarely see SMA.
SMA Type 2 Life Expectancy: Untreated vs Treated Outlook
Before modern treatment, about 70% of people with SMA Type 2 lived to at least their mid-20s, and many lived longer (Healthline, citing StatPearls). Breathing complications were the main cause of shortened life.
That figure comes from untreated children, so it doesn’t describe a child starting treatment today. Specialists now avoid rigid predictions based on type alone (MDA).
What we know about the treated outlook so far:
- Risdiplam held motor gains for at least four years in Type 2 and Type 3 patients (TipRanks, SUNFISH data).
- Some children with SMA Type 2 treated early in life have been reported to gain the ability to walk (SMA News Today).
- These treatments are only about ten years old, so their full effect on lifespan isn’t known yet.
What does this mean for your child’s future? With treatment, good breathing care and regular follow-up, many children grow into adults who study, work and live independently with support.
SMA Type 2 Treatment in India: Access, Generic Risdiplam and Government Support
Risdiplam is the only SMA medicine approved in India, and more than 250 patients were on it by 2025 (Gulati et al., 2025). For most Indian families, the question isn’t which therapy is best in theory. It’s what they can access and sustain for years.
Which treatment can your child access?
Risdiplam is available in India as the branded medicine (Evrysdi) and, since a Delhi High Court decision, as a generic made by Natco Pharma (OC Academy). The generic has made long-term treatment possible for many more families. Talk to your neurologist before switching brands, so dosing and monitoring stay consistent.
The right plan depends on your child’s age, weight, SMN2 copies and current strength, so it’s worked out individually. Book a consultation, or a second opinion if your child already has a diagnosis, to discuss the treatment and support options that suit your family.
Government support under the National Policy for Rare Diseases
SMA is covered by India’s National Policy for Rare Diseases (NPRD) 2021, which supports treatment at notified Centres of Excellence (Ministry of Health and Family Welfare). There are 12 such centres in the country. In April 2026, patient groups reported that many centres had not yet started prescribing the generic (The Week).
Some states go further. Kerala and Rajasthan run state programmes that supply risdiplam to eligible children (Gulati et al., 2025). In Karnataka, a CSR programme supports 50 children with lifelong risdiplam through the state’s centre in Bengaluru (Deccan Herald). Army, ESI and CGHS schemes also cover risdiplam for eligible members.
SMA Type 2 care in Odisha: where families stand today
Families in Odisha face an extra step. None of the 12 national Centres of Excellence for rare diseases is in Odisha (Ministry of Health and Family Welfare). The nearest is the Institute of Post-Graduate Medical Education and Research (IPGMER) in Kolkata. So families seeking NPRD support usually need to register there.
It’s easy to mix this up with another designation. AIIMS Bhubaneswar has been named a Centre of Excellence for sickle cell disease (Medical Dialogues), not for SMA. As of October 2026, Odisha does not have a dedicated state scheme for SMA medicines or SMA newborn screening.
What this means in practice: get the diagnosis, baseline tests and supportive care close to home in Bhubaneswar, then work with your specialist on registration for treatment.
Genetic testing and carrier screening in Bhubaneswar
With about 3% of Indians carrying an SMN1 change, carrier testing makes sense for some couples (MoHFW SMA note). Consider it if:
- SMA or an unexplained infant death runs in either family
- You already have a child with SMA and are planning another pregnancy
- You are related by blood to your partner
If your baby isn’t sitting steadily by 9 months or feels floppy, ask for an early genetic test rather than waiting. A genetic counsellor can explain results and options for future pregnancies.
Getting Evaluated for SMA in Bhubaneswar
If you’re searching for a paediatric neurologist near me in Bhubaneswar because your child is weak or slow to sit, start with an evaluation. You don’t need a confirmed diagnosis to book. At Hi-Tech Medical College & Hospital, families can access:
- Paediatric and neurology consultation for children with low tone or delayed milestones
- EMG and nerve conduction studies
- Sample collection and referral for SMN1 and SMN2 genetic testing
- Paediatric physiotherapy and positioning advice
- Respiratory assessment and follow-up for chest infections
- Second opinions, and guidance on referral to a national Centre of Excellence for treatment support
Hi-Tech Medical College & Hospital, Health Park, Pandara, Bhubaneswar, Odisha 751025
Book a consultation with our paediatric neurology team.
Frequently Asked Questions About SMA Type 2
What is the life expectancy of a child with SMA Type 2?
Without treatment, about 70% of people with SMA Type 2 lived to at least their mid-20s, and many lived longer. That data predates modern therapy. With today’s treatments and good breathing care, the outlook is likely better, but long-term lifespan data isn’t available yet because these medicines are only about ten years old.
Can a child with SMA Type 2 walk?
Without treatment, most children with SMA Type 2 sit but don’t walk on their own. Treatment can change this. Some children treated early have been reported to walk, and others gain standing with braces and a walker. Every child responds differently, so your physiotherapist will set realistic goals.
Is there a cure for SMA Type 2?
No, there’s no cure yet. Disease-modifying therapies such as risdiplam, nusinersen and gene therapy can slow or stop the loss of movement and sometimes improve strength. A muscle-targeted medicine, apitegromab, was approved in the US in September 2026 for use alongside these treatments. Research continues.
Can gene therapy be given to a child with SMA Type 2 older than 2 years?
In the United States, yes. Itvisma, an intrathecal gene therapy, was approved on 24 November 2025 for people with SMA aged 2 and older. It is given once, as a fixed dose into the spinal fluid. It is not approved in India as of October 2026.
Can I get a second opinion for SMA Type 2 in Bhubaneswar?
Yes. If your child was diagnosed elsewhere, a second opinion can confirm the diagnosis, review genetic results and SMN2 copies, and check breathing, spine and feeding needs. At HMCH in Pandara, our team can review your child’s records and discuss treatment and support options. Bring all reports and recent videos of movement.
Is generic risdiplam as effective as the branded version?
A generic contains the same active ingredient and must meet Indian regulatory standards for quality. Patient groups report it as clinically effective. Still, discuss any switch with your child’s neurologist first, so the dose, preparation and monitoring stay the same and any change in your child’s strength is tracked.
Does the government of India support SMA treatment?
Yes. SMA is covered under the National Policy for Rare Diseases 2021, which supports treatment at 12 notified Centres of Excellence. Kerala and Rajasthan run state programmes that supply risdiplam, and Army, ESI and CGHS schemes cover it for eligible members. Book a consultation to understand which route fits your child.
Where can I get an SMA genetic test in Bhubaneswar?
Ask a paediatric neurologist or paediatrician to order an SMN1 and SMN2 genetic test. The sample is a simple blood draw. At HMCH in Pandara, our team can examine your child, arrange the test through an accredited lab and explain the result with genetic counselling.
Which is the best hospital for SMA evaluation in Bhubaneswar?
Look for a hospital with a paediatric neurologist, EMG and nerve conduction testing, access to genetic testing, paediatric physiotherapy and respiratory care under one roof. Ask whether the team will coordinate with a national Centre of Excellence for treatment. HMCH offers evaluation, supportive care and referral support for families in Odisha.
If we have one child with SMA, what is the risk for our next baby?
If both parents are carriers, each pregnancy has a 1 in 4 chance of SMA, a 1 in 2 chance of a carrier child and a 1 in 4 chance of a child who is neither. Genetic counselling and prenatal testing can help you plan.
How do I find a paediatric neurologist near me in Bhubaneswar for SMA?
Start with your child’s paediatrician, who can refer you to a paediatric neurologist. In Bhubaneswar, HMCH at Health Park, Pandara, offers paediatric neurology consultation for children with weakness or delayed milestones. Bring your child’s growth and milestone records and any videos showing how they sit and move.
Summary
SMA Type 2 is a serious genetic condition, but it’s no longer one families face without options. Early genetic testing, a treatment plan and steady supportive care make a real difference. If you’re worried about your child’s sitting, strength or breathing, book an evaluation today.
This article is for general information and is not medical advice. Please consult a qualified doctor for diagnosis and treatment.
